Background: Exchange transfusion (ET) for severe neonatal hyperbilirubinemia (SNH) is frequently undertaken in low- and middle-income countries (LMIC), in sharp contrast to the prevailing practice in high-income countries. However, the criteria for initiating this procedure in settings with limited resources for treating infants with SNH have not been systematically explored. Objective: To identify key considerations for initiating ET in resource-poor countries to curtail its unnecessary use for the prevention of kernicterus. Methods: A review of the existing guidelines and literature on the management of neonatal hyperbilirubinemia worldwide was conducted to identify criteria and underlying factors for initiating ET. Results: There is a dearth of evidence from randomized clinical trials to support clear criteria for indicated ET worldwide. Because risk assessment for kernicterus based solely on the levels of total serum bilirubin (TSB) has often proved inadequate, a combination of plasma/serum bilirubin estimation and clinical evaluation for acute bilirubin encephalopathy (ABE) has been recommended for predicting the risk of kernicterus. However, there is a lack of consistency regarding the TSB levels for which ET should be initiated in relation to the clinical signs/symptoms of ABE and hemolytic disorders. Conclusions: A decision-making framework that combines TSB thresholds and evidence of neurotoxicity is needed for evaluating the risk of kernicterus and prioritising infants for ET in LMICs to curtail unnecessary interventions.

Keywords:
Hemolysis, Developing countries, Bilirubin encephalopathy, Kernicterus, Neurotoxicity
1.
Diamond LK: Replacement transfusion as a treatment for erythroblastosis fetalis. Pediatrics 1948;2:520-524.
2.
National Institute for Health and Clinical Excellence: Neonatal jaundice: clinical guideline 98. 2010. http://www.nice.org.uk/CG98 (accessed July 14, 2015).
3.
Ip S, Chung M, Kulig J, O'Brien R, Sege R, Glicken S, Maisels MJ, Lau J; American Academy of Pediatrics Subcommittee on Hyperbilirubinemia: An evidence-based review of important issues concerning neonatal hyperbilirubinemia. Pediatrics 2004;114:e130-e153.
4.
Salas AA, Mazzi E: Exchange transfusion in infants with extreme hyperbilirubinemia: an experience from a developing country. Acta Paediatr 2008;97:754-758.
5.
Murki S, Kumar P: Blood exchange transfusion for infants with severe neonatal hyperbilirubinemia. Semin Perinatol 2011;35:175-184.
6.
Jackson JC: Adverse events associated with exchange transfusion in healthy and ill newborns. Pediatrics 1997;99:E7.
7.
American Academy of Pediatrics: Management of hyperbilirubinaemia in the newborn infant 35 or more weeks of gestation. Pediatrics 2004;114:297-316.
8.
Steiner LA, Bizzarro MJ, Ehrenkranz RA, Gallagher PG: A decline in the frequency of neonatal exchange transfusions and its effect on exchange-related morbidity and mortality. Pediatrics 2007;120:27-32.
9.
Chitty HE, Ziegler N, Savoia H, Doyle LW, Fox LM: Neonatal exchange transfusions in the 21st century: a single hospital study. J Paediatr Child Health 2013;49:825-832.
10.
Owa JA, Ogunlesi TA: Why we are still doing so many exchange blood transfusion for neonatal jaundice in Nigeria. World J Pediatr 2009;5:51-55.
11.
Hameed NN, Na' Ma AM, Vilms R, Bhutani VK: Severe neonatal hyperbilirubinaemia and adverse short-term consequences in Baghdad, Iraq. Neonatology 2011;100:57-63.
12.
Rasul CH, Hasan MA, Yasmin F: Outcome of neonatal hyperbilirubinemia in a tertiary care hospital in Bangladesh. Malays J Med Sci 2010;17:40-44.
13.
Iskander I, Gamaleldin R, Kabbani M: Root causes for late presentation of severe neonatal hyperbilirubinaemia in Egypt. East Mediterr Health J 2012;18:882-887.
14.
Murray NA, Roberts IA: Neonatal transfusion practice. Arch Dis Child Fetal Neonatal Ed 2004;89:F101-F107.
15.
Canadian Paediatric Society: Guidelines for detection, management and prevention of hyperbilirubinemia in term and late preterm newborn infants (35 or more weeks' gestation). Paediatr Child Health 2007;12:1B-12B.
16.
Bratlid D, Nakstad B, Hansen TW: National guidelines for treatment of jaundice in the newborn. Acta Paediatr 2011;100:499-505.
17.
Ebbesen F, Bjerre JV, Vandborg PK: Relation between serum bilirubin levels ≥450 μmol/l and bilirubin encephalopathy; a Danish population-based study. Acta Paediatr 2012;101:384-389.
18.
Dijk PH, de Vries TW, de Beer JJ; Dutch Pediatric Association: Guideline ‘Prevention, diagnosis and treatment of hyperbilirubinemia in the neonate with a gestational age of 35 or more weeks' (in Dutch). Ned Tijdschr Geneeskd 2009;153:A93.
19.
Swiss Society of Neonatology: Assessment and treatment of jaundiced newborn infants 35 0/7 or more weeks of gestation. http://www.neonet.ch/assets/pdf/2006_Bili-Empfehlungen_e_final.pdf.
20.
Romagnoli C, Barone G, Pratesi S, Raimondi F, Capasso L, Zecca E, Dani C; Task Force for Hyperbilirubinaemia of the Italian Society of Neonatology: Italian guidelines for management and treatment of hyperbilirubinaemia of newborn infants ≥ 35 weeks' gestational age. Ital J Pediatr 2014;40:11.
21.
Queensland Maternity and Neonatal Clinical Guidelines Program: Queensland Maternity and Neonatal Clinical Guideline: Neonatal Jaundice. 2012. http://www.health.qld.gov.au/qcg/documents/g_jaundice.pdf.
22.
Auckland District Health Board: Newborn Services Clinical Guideline: Management of Neonatal Jaundice. 2012. http://www.adhb.govt.nz/newborn/Guidelines/GI/Jaundice.htm.
23.
Kaplan M, Merlob P, Regev R: Israel guidelines for the management of neonatal hyperbilirubinemia and prevention of kernicterus. J Perinatol 2008;28:389-397.
24.
Horn AR, Kirsten GF, Kroon SM, Henning PA, Möller G, Pieper C, et al: Phototherapy and exchange transfusion for neonatal hyperbilirubinaemia: neonatal academic hospitals' consensus guidelines for South African hospitals and primary care facilities. S Afr Med J 2006;96:819-24.
25.
National Neonatal Forum of India: Management of neonatal hyperbilirubinemia. http://www.nnfpublication.org.
26.
Mishra S, Agarwal R, Deorari AK, Paul VK: Jaundice in the newborns. Indian J Pediatr 2008;75:157-163.
27.
Postgraduate Institute of Medical Education and Research: Jaundice; in Dutta S, Kumar P (eds): The PGI NICU Handbook of Protocols, ed 4. Chandigarh, The New Heart Trust, 2010.
28.
Ministry of Health of the Republic of Kenya: Basic Paediatric Protocols for Ages up to 5 Years. Nairobi, Ministry of Health of the Republic of Kenya, 2013, pp 40-42.
29.
Ministry of Health of Malaysia: Management of jaundice in healthy term newborns: Clinical practice guidelines. 2003. http://www.acadmed.org.my/index.cfm?&menuid=67.
30.
World Health Organization: Pocket Book of Hospital Care for Children, ed 2: Guidelines for the Management of Common Childhood Illnesses. Geneva, WHO, 2013.
31.
Gamaleldin R, Iskander I, Seoud I, Aboraya H, Aravkin A, Sampson PD, Wennberg RP: Risk factors for neurotoxicity in newborns with severe neonatal hyperbilirubinemia. Pediatrics 2011;128:e925-e931.
32.
Olusanya BO, Osibanjo FB, Mabogunje CA, Slusher TM, Olowe SA: The burden and management of neonatal jaundice in Nigeria: a scoping review of the literature. Niger J Clin Pract, in press.
33.
Mollison PL, Walker W: Controlled trials of the treatment of haemolytic disease of the newborn. Lancet 1952;1:429-433.
34.
Dijk PH, Hulzebos CV: An evidence-based view on hyperbilirubinaemia. Acta Paediatr Suppl 2012;101:3-10.
35.
Olusanya BO, Ogunlesi TA, Kumar P, Boo NY, Iskander IF, de Almeida MF, Vaucher YE, Slusher TM: Management of late-preterm and term infants with hyperbilirubinaemia in resource-constrained settings. BMC Pediatr 2015;15:39.
36.
De Luca D, Jackson GL, Tridente A, Carnielli VP, Engle WD: Transcutaneous bilirubin nomograms: a systematic review of population differences and analysis of bilirubin kinetics. Arch Pediatr Adolesc Med 2009;163:1054-1059.
37.
Coda Zabetta CD, Iskander IF, Greco C, Bellarosa C, Demarini S, Tiribelli C, Wennberg RP: Bilistick: a low-cost point-of-care system to measure total plasma bilirubin. Neonatology 2013;103:177-181.
38.
Watchko JF: Recent advances in the management of neonatal jaundice. Res Rep Neonatol 2014;4:183-193.
39.
Ahlfors CE: Predicting bilirubin neurotoxicity in jaundiced newborns. Curr Opin Pediatr 2010;22:129-133.
40.
Hulzebos CV, Dijk PH: Bilirubin-albumin binding, bilirubin/albumin ratios, and free bilirubin levels: where do we stand? Semin Perinatol 2014;38:412-421.
41.
Iskander I, Gamaleldin R, El Houchi S, El Shenawy A, Seoud I, El Gharbawi N, Abou-Youssef H, Aravkin A, Wennberg RP: Serum bilirubin and bilirubin/albumin ratio as predictors of bilirubin encephalopathy. Pediatrics 2014;134:e1330-e1339.
42.
Maisels MJ, Bhutani VK, Bogen D, Newman TB, Stark AR, Watchko JF: Hyperbilirubinemia in the newborn infant > or = 35 weeks' gestation: an update with clarifications. Pediatrics 2009;124:1193-1198.
43.
Olusanya BO, Emokpae AA, Zamora TG, Slusher TM: Addressing the burden of neonatal hyperbilirubinaemia in countries with significant glucose-6-phosphate dehydrogenase deficiency. Acta Paediatr 2014;103:1102-1109.
44.
Christensen RD, Yaish HM, Lemons RS: Neonatal hemolytic jaundice: morphologic features of erythrocytes that will help you diagnose the underlying condition. Neonatology 2014;105:243-249.
45.
Olusanya BO, Ogunlesi TA, Slusher TM: Why is kernicterus still a major cause of death and disability in low-income and middle-income countries? Arch Dis Child 2014;99:1117-1121.
46.
Johnson L, Brown AK, Bhutani VK: BIND - a clinical score for bilirubin induced dysfunction in newborns. Pediatrics 1999;104:746-747.
47.
Radmacher PG, Groves FD, Owa JA, Ofovwe GE, Amuabunos EA, Olusanya BO, Slusher TM: Evaluating the severity of neonatal jaundice using a Modified bind score in a resource-constrained setting. BMC Pediatr 2015;15:28.
48.
Newman TB, Liljestrand P, Jeremy RJ, Ferriero DM, Wu YW, Hudes ES, Escobar GJ; Jaundice and Infant Feeding Study Team: Outcomes among newborns with total serum bilirubin levels of 25 mg per deciliter or more. N Engl J Med 2006;354:1889-1900.
49.
Sgro M, Campbell D, Barozzino T, Shah V: Acute neurological findings in a national cohort of neonates with severe neonatal hyperbilirubinemia. J Perinatol 2011;31:392-396.
50.
Kuzniewicz MW, Wickremasinghe AC, Wu YW, McCulloch CE, Walsh EM, Wi S, Newman TB: Incidence, etiology, and outcomes of hazardous hyperbilirubinemia in newborns. Pediatrics 2014;134:504-509.
51.
Kaplan M, Bromiker R, Hammerman C: Severe neonatal hyperbilirubinemia and kernicterus: are these still problems in the third millennium? Neonatology 2011;100:354-362.
52.
Bhutani VK, Johnson L: The jaundiced newborn in the emergency department: prevention of kernicterus. Clin Ped Emerg Med 2008;9:149-159.
53.
Edris AA, Ghany EA, Razek AR, Zahran AM: The role of intensive phototherapy in decreasing the need for exchange transfusion in neonatal jaundice. J Pak Med Assoc 2014;64:5-8.
54.
Slusher TM, Olusanya BO, Vreman HJ, Brearly AM, Vaucher YE, Lund TC, Wong RJ, Emokpae AA, Stevenson DK: A randomized trial of filtered sunlight phototherapy in African neonates. New Engl J Med 2015;373:1115-1124.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.